BPG is committed to discovery and dissemination of knowledge
Articles in Press
5/24/2025 1:14:41 AM | Browse: 95 | Download: 26
Publication Name World Journal of Hepatology
Manuscript ID 105899
Country Poland
Category Infectious Diseases
Manuscript Type Retrospective Study
Article Title Sex-related differences in patients with chronic hepatitis C infection treated with direct-acting antiviral drugs
Manuscript Source Invited Manuscript
All Author List Krystyna Dobrowolska, Dorota Zarębska-Michaluk, Malgorzata Pawłowska, Magdalena Tudrujek-Zdunek, Beata Lorenc, Hanna Berak, Ewa Janczewska, Włodzimierz Mazur, Justyna Janocha-Litwin, Jakub Klapaczyński, Marek Sitko, Dorota Dybowska, Anna Parfieniuk-Kowerda, Anna Piekarska, Jerzy Jaroszewicz and Robert Flisiak
Funding Agency and Grant Number
Corresponding Author Dorota Zarębska-Michaluk, PhD, Professor, Department of Infectious Diseases and Allergology, Jan Kochanowski University, Żeromskiego 5, Kielce 25-369, Poland. dorota1010@tlen.pl
Key Words Women; Hepatitis C virus; Direct-acting antivirals; Menopause; Chronic hepatitis C
Core Tip Sex is the factor influencing the risk of hepatitis C virus infection and the natural course of the disease. An analysis of nearly 19000 patients treated with direct-acting antivirals for chronic hepatitis C according to sex and reproductive status documented that regardless of age, women have lower body mass index, less frequent infection with genotype 3, less frequent co-infections with hepatitis B and human immunodeficiency viruses, and less advanced liver disease. Antiviral treatment is more effective in women than in men, irrespective of age, but postmenopausal women have relatively the lowest effectiveness and the highest incidence of adverse events.
Citation <p>Dobrowolska K, Zarębska-Michaluk D, Pawłowska M, Tudrujek-Zdunek M, Lorenc B, Berak H, Janczewska E, Mazur W, Janocha-Litwin J, Klapaczyński J, Sitko M, Dybowska D, Parfieniuk-Kowerda A, Piekarska A, Jaroszewicz J, Flisiak R. Sex-related differences in patients with chronic hepatitis C infection treated with direct-acting antiviral drugs. <i>World J Hepatol</i> 2025; 17(6): 105899</p>
Received
2025-02-10 08:08
Peer-Review Started
2025-02-19 08:57
To Make the First Decision
Return for Revision
2025-04-07 12:37
Revised
2025-04-18 18:42
Second Decision
2025-05-22 02:42
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief
2025-05-24 01:14
Articles in Press
2025-05-24 01:14
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2025-06-16 08:21
ISSN 1948-5182 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com